Showing 1461-1470 of 1576 results for "".
- J&J Vision Presents Data Validating Improved Surgical Outcomes and Surgeon Satisfaction at ASCRShttps://modernod.com/news/johnson-johnson-vision-presents-data-validating-improved-surgical-outcomes-and-surgeon-satisfaction-across-cataract-and-refractive-portfolio-at-ascrs/2480787/Johnson & Johnson Vision will present and/or support 46 company-sponsored and investigator-led studies evaluating innovations and outcomes across its surgical portfolio at the 2022 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, DC, April 22-26.
- Alcon Announces Scientific Program at ASCRS 2022https://modernod.com/news/alcon-announces-scientific-program-at-ascrs-2022/2480782/Alcon will once again have a significant scientific presence at the American Society of Cataract and Refractive Surgery (ASCRS) 2022 annual meeting, taking place April 22-26 in Washington, DC. Approximately 150 abstracts feature Alcon’s leading ophthalmic products and equipment—with m
- Eyenovia Announces Poster Presentation at ASCRS 2022https://modernod.com/news/eyenovia-announces-poster-presentation-at-ascrs-2022/2480776/Eyenovia announced that the company will present an ePoster at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, which is being held April 23-26 in Washington, D.C. Details of the ePoster presentation are as follows: <
- Market Scope: Robotic Vitrectomy Debate Still Rages for Retina Surgeonshttps://modernod.com/news/market-scope-robotic-vitrectomy-debate-still-rages-for-retina-surgeons/2480773/The future of robotic vitrectomy continues to be top of mind for retina surgeons, with panelists at nearly every major retina meeting in 2021 debating the topic—and without reaching co
- Graybug to Present at the 2022 ASCRS Annual Meetinghttps://modernod.com/news/graybug-to-present-at-the-2022-ascrs-annual-meeting/2480770/Graybug Vision announced a platform presentation at the upcoming American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, to be held in Washington, D.C. from April 22-26, 2022. Information is listed below and available on the
- Orasis Pharmaceuticals to Present New Data on Novel Presbyopia Candidate at ASCRShttps://modernod.com/news/orasis-pharmaceuticals-to-present-new-data-on-novel-presbyopia-candidate-at-ascrs/2480764/Orasis Pharmaceuticals announced that it will present new data on its novel eye drop candidate, CSF-1, at the 2022 American Society for Cataract and Refractive Surgery (ASCRS) annual meeting being held April 22-26 in Washington, D.C. "We look forward to these present
- Shamir Group Employees Around the World are Mobilized for Humanitarian Aid for Ukrainian Refugees in Warsawhttps://modernod.com/news/shamir-group-employees-around-the-world-are-mobilized-for-humanitarian-aid-for-ukrainian-refugees-in-warsaw/2480745/Shamir is now voluntarily operating traveling laboratories for testing and fitting of eyeglasses among Ukrainian refugees, located at the Patk Expo complex in Warsaw, Poland. The mobile laboratories on wheels are equipped with advanced technology for rapid production of advanced lenses&mdash
- Haag-Streit Introduces the Imaging Module 910 Slit Lamphttps://modernod.com/news/haag-streit-launhces-the-imaging-module-910-slit-lamp/2480718/Haag-Streit announced the launch of the Imaging Module 910 slit lamp. The device is instantly ready by the turn of a knob and does not require using software. Haag-Streit says capturing images is equally easy—pressing the camera trigger button is all that it takes. "
- MeiraGTx Receives Clinical Development Milestone Payment from Janssenhttps://modernod.com/news/meiragtx-receives-clinical-development-milestone-payment-from-janssen/2480599/MeiraGTx Holdings announced that it has received a $30 million payment from Johnson & Johnson's Janssen Pharmaceuticals for a clinical milestone in the phase 3 Lumeos trial of botaretigene sparoparvovec (AAV-RPGR), an investigational gene therapy for the treatment of X-linked retinit
- Harrow Health Acquires US Commercial Rights to Four Branded Eye Drops from Novartishttps://modernod.com/news/harrow-health-imprimisrx-acquires-us-commercial-rights-to-four-branded-eye-drops-from-novartis/2480527/Harrow Health, the parent company of ImprimisRx, announced its has acquired the exclusive US commercialization rights of four FDA-approved ophthalmic medicines—Iopidine 1% and 0.5% (apraclonidine hydroc